ArticleInternational urology and nephrology2025
Proenkephalin A 119-159 as a biomarker for predicting sepsis-associated acute kidney injury.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role of Proenkephalin in Predicting Renal Dysfunction and Mortality in Septic Patients Admitted to the Emergency Department and Intensive Care Unit: A Narrative Review.Journal of personalized medicine · 2026Review
- Research advances on the gut-kidney axis theory in sepsis-associated acute kidney injury.Frontiers in pharmacology · 2026Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study is to assess the predictive value of serum proenkephalin A 119-159 (penKid) levels for acute kidney injury (AKI) associated with sepsis (SA-AKI).
methodsA retrospective cohort study was conducted from September 2021 to September 2022. Clinical characteristics and laboratory parameters were compared between the AKI and non-AKI groups. Risk factors for the development of SA-AKI were identified using Cox regression analysis. In addition, receiver operating characteristic (ROC) curve analysis was conducted to assess the predictive ability of each identified risk factor for AKI among patients with sepsis.
resultsA total of 161 patients diagnosed with sepsis or septic shock were included, among whom 66 developed AKI, representing an incidence rate of 41.0%. Baseline lactic acid (LA) levels were significantly higher in the AKI group compared to the non-AKI group. Similarly, baseline penKid concentrations were significantly elevated in the AKI group compared to the non-AKI group. Serum LA and penKid levels were identified as independent risk factors for AKI in patients with sepsis or septic shock. ROC curve analysis demonstrated that the baseline penKid concentration significantly predicted AKI in this population (p < 0.001), with an area under the curve of 0.867, sensitivity of 0.788, and specificity of 0.832 when the penKid threshold was set at 2.41 μg/L.
conclusionSerum penKid levels may serve as a reliable biomarker for the early detection of AKI in patients presenting with sepsis or septic shock.
Indexed as
Identifiers
40587061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.